Skip to main content

Advertisement

Log in

Retroperitoneal lymph-node dissection after chemotherapy for germ cell cancer in patients with elevated tumor markers

  • Practice Point
  • Published:

From Nature Clinical Practice Urology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Hendry WF et al. (2002) Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer 94: 1668–1676

    Article  Google Scholar 

  2. Christensen TB et al. (1999) Validation of 125I-hCG as a marker for elimination of hCG and stability of 125I-hCG after in vivo injection in humans. Br J Cancer 80: 1582–1587

    Article  CAS  Google Scholar 

  3. Fizazi K (2001) Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy—results from an international study group. J Clin Oncol 19: 2647–2657

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Sandra Ford, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Alan Horwich.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Horwich, A., Huddart, R. Retroperitoneal lymph-node dissection after chemotherapy for germ cell cancer in patients with elevated tumor markers. Nat Rev Urol 3, 250–251 (2006). https://doi.org/10.1038/ncpuro0481

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro0481

  • Springer Nature Limited

Navigation